BR0315659A - Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo - Google Patents

Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo

Info

Publication number
BR0315659A
BR0315659A BR0315659-1A BR0315659A BR0315659A BR 0315659 A BR0315659 A BR 0315659A BR 0315659 A BR0315659 A BR 0315659A BR 0315659 A BR0315659 A BR 0315659A
Authority
BR
Brazil
Prior art keywords
tramadol
salt
pharmaceutical composition
controlled release
once daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0315659-1A
Other languages
English (en)
Inventor
Vicent Lenaerts
Laure Patricia Quadji-Njiki
Jonathan Bacon
Rachid Ouzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO
Original Assignee
Labopharm (Barbados) Ltd
Labopharm Inc
Labopharm Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm (Barbados) Ltd, Labopharm Inc, Labopharm Europe Ltd filed Critical Labopharm (Barbados) Ltd
Priority claimed from PCT/CA2003/001638 external-priority patent/WO2004037222A2/en
Publication of BR0315659A publication Critical patent/BR0315659A/pt
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cereal-Derived Products (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA ORAL PARA ADMINISTRAçãO UMA VEZ AO DIA PARA A LIBERAçãO CONTROLADA DE TRAMADOL OU UM SAL DO MESMO". é prevista uma administração oral de formulação de tramadol de liberação controlada ou um sal do mesmo, que, mediante administração inicial de uma dose, provê um efeito analgésico dentro de 2 horas, e este efeito analgésico continua durante pelo menos 24 horas após a administração.
BR0315659-1A 2002-10-25 2003-10-27 Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo Pending BR0315659A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50906202P 2002-10-25 2002-10-25
US51037803P 2003-10-10 2003-10-10
PCT/CA2003/001638 WO2004037222A2 (en) 2002-10-25 2003-10-27 Sustained-release tramadol formulations with 24-hour efficacy

Publications (1)

Publication Number Publication Date
BR0315659A true BR0315659A (pt) 2005-09-20

Family

ID=35044187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315659-1A Pending BR0315659A (pt) 2002-10-25 2003-10-27 Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo

Country Status (12)

Country Link
US (1) US7988998B2 (pt)
EP (1) EP1594460B1 (pt)
AT (1) ATE390128T1 (pt)
BR (1) BR0315659A (pt)
DE (1) DE60320039T2 (pt)
DK (1) DK1594460T3 (pt)
ES (1) ES2305567T3 (pt)
HK (1) HK1101355A1 (pt)
MX (1) MXPA05004412A (pt)
NZ (1) NZ539870A (pt)
SI (1) SI1594460T1 (pt)
TW (1) TWI319713B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
PL1931346T3 (pl) * 2005-09-09 2013-01-31 Angelini Labopharm Llc Kompozycja trazodonu do podawania raz na dobę
WO2009049405A1 (en) * 2007-10-16 2009-04-23 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
RU2010129907A (ru) 2007-12-17 2012-01-27 Лабофарм Инк. (CA) Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
JP5667575B2 (ja) 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
KR102380825B1 (ko) * 2015-05-29 2022-04-01 삼성전자주식회사 반도체 발광다이오드 칩 및 이를 구비한 발광장치
DK3431078T3 (da) 2017-07-20 2021-04-19 Intas Pharmaceuticals Ltd Orale faste betahistinsammensætninger med ikkepulserende forlænget frigivelse
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
GB1368574A (en) 1971-02-12 1974-10-02 Ives Lab Inc Divisible tablet
US4131675A (en) 1978-02-09 1978-12-26 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of combinations of L-DOPA with trazodone and L-DOPA with etoperidone in Parkinsonism
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
IT1233412B (it) * 1987-12-02 1992-03-30 Acraf Uso del trazodone
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
CA2095523C (en) * 1991-09-06 2004-06-22 Robert B. Raffa Composition comprising a tramadol material and acetaminophen and its use
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
GB2284760B (en) 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
FR2688422A1 (fr) 1992-03-11 1993-09-17 Coletica Microcapsules a parois en polysaccharides contenant des fonctions alcools primaires, et compositions en contenant.
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
KR100304997B1 (ko) 1992-07-24 2002-04-24 드니랑글로아 효소에의해제어되는약물방출을위한가교결합된폴리하이드록실물질을포함하는정제
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
IL103096A (en) * 1992-09-08 1996-12-05 Chemagis Ltd Process for purification 2 -]) Dimethylamino (methyl-1-) 3-methoxycinyl (cyclohexanol and its salts.
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
DE4315525B4 (de) 1993-05-10 2010-04-15 Euro-Celtique S.A. Pharmazeutische Zusammensetzung
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE69408466T2 (de) * 1993-08-24 1998-08-20 Akzo Nobel Nv Linsen zur korrektur von sehfehlern
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
ATE212224T1 (de) 1993-11-23 2002-02-15 Euro Celtique Sa Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5560331A (en) 1994-05-10 1996-10-01 Yamaha Hatsudoki Kabushiki Kaisha Cylinder head for engine
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0807433A4 (en) 1994-12-27 2005-12-28 Akzo Nobel Nv PREPARING WITH DELAYED RELEASE
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
IL116281A (en) * 1995-12-07 1999-06-20 Chemagis Ltd Process for the purification of (rr,ss)-2-dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol and its salts
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
IL119121A (en) * 1996-08-22 2000-11-21 Chemagis Ltd Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride
DE19640062B4 (de) 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
AU744156B2 (en) 1996-10-28 2002-02-14 General Mills Inc. Embedding and encapsulation of controlled release particles
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
NZ336153A (en) * 1996-12-18 2000-06-23 Bimeda Res & Dev Ltd Antiinfective free intramammary veterinary composition comprising a gel and a heavy metal compound for the prevention of mastitis
US5807575A (en) 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US5877351A (en) * 1997-12-24 1999-03-02 Wyckoff Chemical Company, Inc. Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts
JP2002501892A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
HUP0101627A3 (en) 1998-04-14 2003-02-28 Gen Hospital Corp Boston Pharmaceutical compositions for treating neuropsychiatric disorders
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
AU761021B2 (en) 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6245387B1 (en) * 1998-11-03 2001-06-12 Diamon-Fusion International, Inc. Capped silicone film and method of manufacture thereof
US6129205A (en) 1998-12-09 2000-10-10 Ashworth Bros. Inc. Variable loop count conveyor belt
DE19901686A1 (de) 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
DE19901687B4 (de) 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
NZ513037A (en) 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
DE19940740A1 (de) 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
ES2226886T3 (es) * 1999-08-31 2005-04-01 Grunenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
DE19947747A1 (de) 1999-10-05 2001-04-12 Gruenenthal Gmbh Verwendung von (+)-Tramadol, O-Demethyltramadol bzw. (+)-O-Demethyltramadol zur Therapie der Harninkontinenz
PE20010623A1 (es) 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US6211229B1 (en) * 2000-02-17 2001-04-03 Neil B. Kavey Treatment of transient and short term insomnia
US6645537B2 (en) 2000-02-18 2003-11-11 Keurig, Incorporated Beverage filter cartridge
US6326404B1 (en) 2000-02-21 2001-12-04 Gruenenthal Gmbh Use of O-desmethyl-N-mono-desmethyl-tramadol
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
GB0007419D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
GB0009522D0 (en) 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
JP2001353519A (ja) * 2000-06-14 2001-12-25 Suncall Corp 二重構造クラッドパイプ及びその製造方法
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
EP1190712B1 (en) 2000-09-22 2004-09-01 SMB Technology Oral once daily tramadol beads composition
EP2932964A1 (en) * 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20020106408A1 (en) 2000-12-01 2002-08-08 Johnatan Bacon Prolamin-based sustained-release compositions and delayed-onset compositions
JP5502254B2 (ja) * 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形
WO2002069974A1 (en) 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
US6806293B1 (en) 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
US6659373B1 (en) 2001-05-30 2003-12-09 L. R. Nelson One touch actuated valve
US6968551B2 (en) 2001-06-11 2005-11-22 John Hediger System and user interface for generation and processing of software application installation instructions
US6818504B2 (en) * 2001-08-10 2004-11-16 Hynix Semiconductor America, Inc. Processes and structures for self-aligned contact non-volatile memory with peripheral transistors easily modifiable for various technologies and applications
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
MXPA04004035A (es) 2001-10-29 2004-10-29 Labopharm Inc Metodos y formas de dosis para mejorar la biodisponibilidad de agentes terapeuticos.
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
AU2003232805A1 (en) 2002-05-24 2003-12-12 Carl-Fr. Coester Pharmaceutical active substance combination and the use thereof
DE60319252T2 (de) * 2002-09-21 2009-03-05 Zhang, Shuyi Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
SI1558935T1 (sl) 2002-10-25 2008-12-31 Labopharm Inc Nadzorovano sproĺ äśujoäśi sestavek
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
CA2503155A1 (en) 2002-10-25 2004-05-06 Labopharm Inc. Sustained-release tramadol formulations with 24-hour efficacy
US6669929B1 (en) * 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
CN1926728A (zh) * 2004-01-07 2007-03-07 光谱物理学公司 工业用直接二极管泵浦超快速放大器***
BRPI0518322A2 (pt) * 2004-11-16 2008-11-18 Limerick Neurosciences Inc composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica
WO2007025005A2 (en) * 2005-08-24 2007-03-01 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
PL1931346T3 (pl) * 2005-09-09 2013-01-31 Angelini Labopharm Llc Kompozycja trazodonu do podawania raz na dobę
US20070237816A1 (en) 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief

Also Published As

Publication number Publication date
US20070003618A1 (en) 2007-01-04
DE60320039D1 (de) 2008-05-08
DK1594460T3 (da) 2008-07-28
US20090047345A9 (en) 2009-02-19
EP1594460B1 (en) 2008-03-26
MXPA05004412A (es) 2005-11-23
ES2305567T3 (es) 2008-11-01
TWI319713B (en) 2010-01-21
SI1594460T1 (sl) 2008-08-31
ATE390128T1 (de) 2008-04-15
NZ539870A (en) 2007-11-30
DE60320039T2 (de) 2009-05-14
US7988998B2 (en) 2011-08-02
EP1594460A2 (en) 2005-11-16
HK1101355A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
UA84277C2 (ru) Композиция трамадола с пролонгированным высвобождением с 24-часовым действием
MXPA04009977A (es) Formulaciones de tramadol de liberacion sostenida con eficacia clinica durante 24 horas.
HK1101355A1 (en) Sustained-release tramadol formulations with 24-hour efficacy 24
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
TW200738228A (en) Neramexane modified release matrix tablet
JP2009541237A (ja) 様々な型の痛みを予防、軽減及び／又は治療する医薬を製造するための、置換２−アミノテトラリンの使用
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
NO20050771L (no) Bicifadinformulering
BRPI0418973A (pt) composições de risedronato e seus métodos de uso
NO20054646L (no) Doseringskur for ikke-steroidalt anti-inflammatorisk legemiddel
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
BRPI0418770A (pt) combinação antimicobacteriana, composição farmacêutica antimicobacteriana e processo para a preparação de uma composição farmacêutica antimicobacteriana
BR0204889A (pt) Kit para a redução de dor
MA27157A1 (fr) Methode de traitement d'affections osseuses.
BR0213340A (pt) Formulação de medicamento sólida para um derivado de piperazinuréia
BRPI0418122A (pt) formulação farmacêutica de liberação controlada
BRPI0405520A (pt) novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM (BARBADOS) LIMITED (BB) , PALADIN LABS I

B25G Requested change of headquarter approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B25A Requested transfer of rights approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B25D Requested change of name of applicant approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]